NCT03357796View on ClinicalTrials.gov

Relative Bioavailability (RBA) Study of LY03005 vs Pristiq®

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 27, 2017

Primary Completion Date

December 22, 2017

Study Completion Date

December 22, 2017

Conditions
Major Depressive Disorder
Interventions
DRUG

LY03005

80 mg, oral tablets, single dose

DRUG

Pristiq

50 mg, oral tablets, single dose

Trial Locations (1)

07724

Clinilabs, Inc., Eatontown

All Listed Sponsors
lead

Luye Pharma Group Ltd.

INDUSTRY

NCT03357796 - Relative Bioavailability (RBA) Study of LY03005 vs Pristiq® | Biotech Hunter | Biotech Hunter